Safety

RIDADR 

1544

HazardClass 

6.1(a)

PackingGroup 

II

Hazard and Precautionary Statements (GHS)

Papaveretum Chemical Properties,Usage,Production

Clinical Use

Opiate analgesia (15.4 mg/mL) 1 mL contains 10 mg anhydrous morphine, 1.2 mg papaverine HCl, and 1.04 mg codeine HCl

Drug interactions

Potentially hazardous interactions with other drugs
Analgesics: possible opioid withdrawal with buprenorphine and pentazocine.
Anti-arrhythmics: delayed absorption of mexiletine.
Antidepressants: possible CNS excitation or depression with MAOIs – avoid; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics.
Antihistamines: increased sedative effects with sedating antihistamines.
Antipsychotics: enhanced hypotensive and sedative effects.
Dopaminergics: avoid with selegiline.
Nalmefene: avoid concomitant use.
Sodium oxybate: enhanced effect of sodium oxybate – avoid.

Metabolism

Papaverine: Mainly metabolised in the liver and excreted in the urine, almost entirely as glucuronide-conjugated phenolic metabolites.